Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases

2020 ◽  
Vol 24 (8) ◽  
pp. 812-819
Author(s):  
S. Benhmida ◽  
R. Sun ◽  
E. Gherga ◽  
Y. Hammoud ◽  
J. Rouvier ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Hypofractionated Radiotherapy ◽  
Frail Patients

scholarly journals Diagnosis and treatment delay of head and neck cancers during COVID-19 era in a tertiary care academic hospital: what should we expect?

2021 ◽  
Author(s):  
Pietro De Luca ◽  
Antonella Bisogno ◽  
Vito Colacurcio ◽  
Pasquale Marra ◽  
Claudia Cassandro ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Head And Neck ◽  
Retrospective Analysis ◽  
Tertiary Care ◽  
Diagnostic Delay ◽  
Treatment Delay ◽  
Head And Neck Cancers ◽  
Control Measures ◽  
Academic Hospital ◽  
The Impact

Abstract Background Since the spreading of SARS-CoV-2 from China, all deferrable medical activities have been suspended, to redirect resources for the management of COVID patients. The goal of this retrospective study was to investigate the impact of COVID-19 on head and neck cancers’ diagnosis in our Academic Hospital. Methods A retrospective analysis of patients treated for head and neck cancers between March 12 and November 1, 2020 was carried out, and we compared these data with the diagnoses of the same periods of the 5 previous years. Results 47 patients were included in this study. We observed a significative reduction in comparison with the same period of the previous 5 years. Conclusions Our findings suggest that the COVID-19 pandemic is associated with a decrease in the number of new H&N cancers diagnoses, and a substantial diagnostic delay can be attributable to COVID-19 control measures.

Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck cancers treated with intensity modulated radiation therapy (IMRT)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 16513-16513 ◽  
Author(s):  
V. Bar Ad ◽  
S. Both ◽  
P. Dutta ◽  
H. Quon
Keyword(s):  
Radiation Therapy ◽  
Retrospective Study ◽  
Head And Neck ◽  
Pain Control ◽  
Radiation Treatment ◽  
Pain Medication ◽  
Head And Neck Cancers ◽  
Median Dose ◽  
Concomitant Boost ◽  
Radiation Induced

16513 Background: Gabapentin has been reported to effectively treat multiple neuropathic pain syndromes. This retrospective study evaluates the efficacy of gabapentin for the treatment of pain related to radiation induced mucositis, in patients with head and neck cancers, treated with radiation therapy (RT). Methods: This retrospective study includes 30 pts with head and neck cancers, treated with RT, without concomitant or induction chemotherapy. IMRT planning was performed using a concomitant boost technique with a median dose of 54 Gy, 63 Gy, and 66 Gy delivered to the low risk clinical tumor volume (CTV), high risk CTV and boost target volume, respectively, using 30- 34 fractions. The dose of gabapentin was gradually increased starting on the second week of RT from 600 mg/day to the dose of 2700 mg/d over the course of one week. Narcotic pain medication (Roxicodone) was prescribed as needed. Results: 26 (86%) pts required no pain medication during the first two weeks of RT, despite the presence of grade 1 and/or 2 mucositis in 24 of them. During the third and fourth weeks of RT, 28 (93%) pts were treated with a median dose of 2700 mg/day of gabapentin, with only 3 (10%) pts requiring low dose narcotic pain medication, 15–30 mg/day of Roxicodone, added to gabapentin for adequate pain control, despite grade 2 or higher mucositis in 22 pts. During weeks 5 and 6, 28 (93%) pts continued to be treated with a median dose of 2700 mg/day of gabapentin with only 10 (35%) pts requiring 15–40 mg/day of Roxicodone, in addition to gabapentin for pain control, despite the presence of grade 2 or higher mucositis in 23 pts. Only 3% of the pts in this group had delay in RT delivery. Gabapentin was well tolerated with only 13% of pts experiencing mild side effects (somnolence, nausea, or vomiting), which were managed with reducing the dose or changing the dosing schedule. Conclusions: Gabapentin is effective and well-tolerated for the treatment of mucositis-induced pain related to radiation treatment in patients with head and neck cancers, treated with IMRT. We further demonstrate that the use of gabapentin at doses of 2700 mg per day can reduce or eliminate the need for narcotic pain medication. No significant financial relationships to disclose.

Endovascular Management of Patients with Head and Neck Cancers Presenting with Acute Hemorrhage: A Single-Center Retrospective Study

2016 ◽  
Vol 40 (4) ◽  
pp. 510-519 ◽  
Author(s):  
P. P. Vilas Boas ◽  
L. H. de Castro-Afonso ◽  
L. M. Monsignore ◽  
G. S. Nakiri ◽  
F. V. de Mello-Filho ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Endovascular Management ◽  
Single Center ◽  
Acute Hemorrhage

scholarly journals Incidence of Lymphatic Metastasis to Neck Nodes Level IIb in Neck Dissection for Head and Neck Cancers: A Retrospective Study

2014 ◽  
Vol 5 (3) ◽  
pp. 99-103
Author(s):  
Faisal Al Zahrani ◽  
Khalid Al-Qahtani ◽  
Mohammed Alshahrani ◽  
Khamis Almufargi ◽  
Abdullah Alkhudhayri ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Lymph Nodes ◽  
Head And Neck ◽  
Neck Dissection ◽  
Lymphatic Metastasis ◽  
Head And Neck Cancers ◽  
Surgical Removal ◽  
Selective Neck Dissection ◽  
Fisher Exact Test ◽  
Lymph Nodes Metastasis

ABSTRACT Introduction Selective neck dissection (SND) is performed to prevent head and neck cancers metastasis. We tried to determine the incidence of level IIb lymph nodes metastasis and it is associations in head and neck cancers for selection of patients requiring SND. Materials and methods A retrospective study was conducted on 57 patients who underwent surgical removal of the head and neck tumor by 84 neck dissections. Fisher exact test was used to measure the association between positive IIb nodes and the other variables. Results Nine (15.8%) of 57 patients showed level IIb lymph nodes metastasis comprising 10.71% of the 84 neck dissections. Six (66.66%) were associated with oral cavity cancers, 8 (88.9%) with squamous cell carcinoma (SCC), 6 (66.66%) with T4 tumor. Five (55.6%) were N2b, and 7 (77.8%) were found in N+ necks. All (100%) positive IIb nodes were associated with metastatic level IIa. Significant associations were found betweenpositive IIbnodesand N2b (p= 0.005), clinically N+ necks (p = 0.005) and IIa (p < 0.01). Conclusion The incidence of level IIb nodes metastasis is high so they should be removed in any oral tumor, SCC, advanced staging, N+ necks or positive IIa lymph nodes metastasis. How to cite this article Al zahrani F, Al-Qahtani K, Alshahrani m, Almufargi K, Alkhudhayri A, Obad l, Islam T. Incidence of lymphatic metastasis to Neck Nodes level IIb in Neck Dissection for Head and Neck Cancers: A Retrospective Study. Int J Head Neck Surg 2014;5(3):99-103.

scholarly journals Burden of head and neck cancers in Kamrup urban district cancer registry of Assam, India: a retrospective study

2014 ◽  
Vol 2 (4) ◽  
pp. 1382
Author(s):  
Jagannath Sharma ◽  
Debanjana Barman ◽  
Mridul Sarma ◽  
Arpita Sharma ◽  
Manoj Kalita ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Head And Neck ◽  
Cancer Registry ◽  
Head And Neck Cancers ◽  
Urban District

scholarly journals Cancers Primitifs Oto-Rhino-Laryngologiques Et Cervico-Maxillo-Faciaux De L’enfant: Aspects Épidémiologiques Et Histopathologiques

2016 ◽  
Vol 12 (24) ◽  
pp. 389
Author(s):  
Foma W. ◽  
Amana B. ◽  
Pegbessou E. ◽  
Bissa H. ◽  
Adam S. ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Oral Cavity ◽  
Head And Neck ◽  
Teaching Hospital ◽  
Head And Neck Cancers ◽  
Hodgkin's Lymphoma ◽  
Pathological Anatomy ◽  
Reference Centre ◽  
Non Hodgkin's Lymphoma ◽  
Anatomy Laboratory

Objective: Have a view on child’s head and neck cancers in a reference centre in Togo. Methodology: It was a descriptive retrospective study about the cancers diagnosed among children under 15 years in head and neck department of Sylvanus Olympio Teaching Hospital of Lomé in Togo from 1st January 2005 to 31 December 2014. The pieces were analysed in the pathological anatomy laboratory of the same teaching Hospital. Results: The child’s head and neck cancers represented 0.8 % of the whole ENT tumours and 5.5% of head and neck cancers. The average age was 8 years ± 4.7 ranging from 3 months to 15 years. The male sexe was predominant in 15 cases. The frequent location was ganglions, followed by oral cavity (gingivo-maxillary location and gingivo-mandibular location) in respectively 13 and 6 cases. The sinus, rhinopharynx, and larynx locations were found in 01 case of each cancer. In terms of histopathology, there were 21 cases of non-Hodgkin’s lymphoma of which 09 cases of Burkitt’s and 01 case of inferior lip neuroblastoma. Conclusion: Child’s head and neck cancers are scarce in Togo and dominated by malignant primitive cervical adenopathy.

Sign in / Sign up

Export Citation Format

Share Document